Jason Zemansky
Stock Analyst at B of A Securities
(0)
# 4322
Out of 5,319 analysts
38
Total ratings
46.67%
Success rate
-14.60%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
CYTK Cytokinetics | Maintains: Neutral | 62 54 | 39.48 | 36.78% | 4 | Apr 15, 2025 | |
INSM Insmed | Maintains: Strong Buy | 92 96 | 72.65 | 32.14% | 9 | Mar 20, 2025 | |
RCUS Arcus Biosciences | Maintains: Neutral | 22 17 | 7.88 | 115.74% | 5 | Feb 19, 2025 | |
KURA Kura Oncology | Maintains: Buy | 36 29 | 5.9 | 391.53% | 2 | Nov 22, 2024 | |
SNDX Syndax Pharmaceutica... | Maintains: Strong Buy | 30 31 | 11.54 | 168.63% | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underperform | 3 3 | 0.95 | 163.16% | 5 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Underperform | 391 23 | n/a | n/a | 2 | Dec 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 230 | n/a | n/a | 1 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 9 10 | 0.92 | 986.96% | 4 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 450 162 | n/a | n/a | 1 | Feb 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 145 155 | 0.33 | 46869.7% | 2 | Dec 13, 2021 |